The overall response rate (ORR, i.e., patients achieving a complete (CR)- or partial (PR) remission) in clinical trials with anti-CD19 CAR-T cells for aggressive B cell lymphomas and B-ALL ranges from 52% to 83% [20,21,22]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.